Hutchison China MediTech Limited (“Chi-Med” or the “Company”) (AIM/Nasdaq: HCM), the commercial-stage biopharmaceutical company focused on discovery, development and commercialization of targeted therapies and immunotherapies for oncology and immunological diseases, is pleased to announce today that it has submitted a listing application on Form A1 to The Stock Exchange of Hong Kong
April 16, 2019
· 13 min read